Metastasis Rate High After Resection of High-Risk Esophageal Cancers Metastasis Rate High After Resection of High-Risk Esophageal Cancers
The annual metastasis rate after radical endoscopic resection of high-risk intramucosal esophageal adenocarcinoma is nearly 7%, indicating a need for close follow-up, a retrospective study suggests.Reuters Health Information (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - March 23, 2022 Category: Gastroenterology Tags: Hematology-Oncology News Source Type: news
Fecal Microbiota - Based Screening Feasible for Pancreatic Cancer
Fecal metagenomics classifiers better than salivary - based classifiers for identifying pancreatic ductal adenocarcinoma (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - March 9, 2022 Category: Cancer & Oncology Tags: Gastroenterology, Oncology, Pathology, Journal, Source Type: news
Fecal Microbiota-Based Screening Feasible for Pancreatic Cancer
WEDNESDAY, March 9, 2022 -- Fecal microbiota-based screening seems feasible for early detection of pancreatic ductal adenocarcinoma (PDAC), according to a study published online March 8 in Gut.
Ece Kartal, Ph.D., from the European Molecular Biology... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 9, 2022 Category: Pharmaceuticals Source Type: news
Pancreatic Cancer Identified by Fecal Microbiota Panel Pancreatic Cancer Identified by Fecal Microbiota Panel
A specific panel of fecal microbiota can distinguish pancreatic ductal adenocarcinoma from other high-risk disease types.Medscape Medical News (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - March 9, 2022 Category: Pathology Tags: Hematology-Oncology News Source Type: news
Model Using Routine Clinical Data May Predict Pancreatic Cancer Risk
MONDAY, Feb. 14, 2022 -- A model using routine clinical information can predict pancreatic ductal adenocarcinoma (PDA) following diagnosis of impaired fasting glucose (IFG), according to a study published in the January issue of the European Journal... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 14, 2022 Category: Pharmaceuticals Source Type: news
Endometrial Cancer Characteristics and Risk of Recurrence Endometrial Cancer Characteristics and Risk of Recurrence
This study describes the clinicopathologic characteristics and survival outcomes of endometrial adenocarcinomas stratified by mismatch repair status.American Journal of Clinical Pathology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 4, 2022 Category: Consumer Health News Tags: Pathology & Lab Medicine Journal Article Source Type: news
“There’s something down there…”
Discussion:
Breast tissue develops from “milk lines” of the ectoderm that extend along the anterior abdominal wall from the axilla to the labia majora. While normal breast development occurs on the upper chest, breast tissue can develop anywhere along these lines. [Fallat, Greydanus] Polythelia is the presence of an accessory nipple, and is found in 1-2% of the population, and is slightly more common in males. [Greydanus] Removal can be done for cosmetic reasons should the patient desire.
Polymastia or accessory breast tissue may be found as well, but is less common than polythelia alone. Like normal breast tissue, ect...
Source: EPMonthly.com - February 1, 2022 Category: Emergency Medicine Authors: Jeffrey Lyles Source Type: news
Young Have Greatest Burden of Distant Colorectal Adenocarcinoma
Largest increases in distant - stage proportion for rectal - only seen for 20 - to 29 - year - old non - Hispanic Blacks, Hispanics (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - January 27, 2022 Category: Cancer & Oncology Tags: Family Medicine, Gastroenterology, Internal Medicine, Oncology, Pathology, Journal, Source Type: news
Young Have Greatest Burden of Distant Colorectal Adenocarcinoma
THURSDAY, Jan. 27, 2022 -- The youngest adults have the greatest burden of distant-stage early-onset colorectal adenocarcinoma, according to a study published online Jan. 26 in Cancer Epidemiology, Biomarkers& Prevention.
Eric M. Montminy,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 27, 2022 Category: Pharmaceuticals Source Type: news
Latest Phase 3 Data for First-in-Class TREMFYA ® (guselkumab) Demonstrates Significant and Durable Improvement in Signs and Symptoms of Active Psoriatic Arthritis while Maintaining its Safety Profile in Patients with Inadequate Response to Tumor Necrosis Factor Inhibition (TNFi-IR)
SPRING HOUSE, PENNSYLVANIA, December 3, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new TREMFYA® (guselkumab) efficacy and safety data from the Phase 3b COSMOS trial published in Annals of the Rheumatic Diseases (ARD), evaluating this selective interleukin (IL)-23 inhibitor in adults with active psoriatic arthritis (PsA) who demonstrated inadequate efficacy or intolerance to tumor necrosis factor inhibition (TNFi).1 Results showed significantly higher proportions of patients treated with TREMFYA had improvement in joint signs and symptoms and complete skin clearance versus placeb...
Source: Johnson and Johnson - December 3, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Esophageal Cancer Requires Long-term Postop Surveillance Esophageal Cancer Requires Long-term Postop Surveillance
Endoscopic resection of T1 esophageal adenocarcinoma is associated with excellent overall survival, yet long-term surveillance is still required for possible recurrence.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - November 19, 2021 Category: Gastroenterology Tags: Gastroenterology News Source Type: news
Family History and Risk of Barrett's Esophagus Family History and Risk of Barrett's Esophagus
How much impact does family history have on the risk of developing Barrett ' s esophagus or esophageal adenocarcinoma?Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 18, 2021 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
New Data on RYBREVANT ® (amivantamab-vmjw) in Combination with Lazertinib Show Early Activity in Patients with Non-Small Cell Lung Cancer Whose Disease Has Progressed After Both Osimertinib and Platinum-Based Chemotherapy
September 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced preliminary results from the Phase 1b CHRYSALIS-2 (NCT04077463) study evaluating RYBREVANT® (amivantamab-vmjw) in combination with lazertinib in the treatment of patients with non-small cell lung cancer (NSCLC) characterized by epidermal growth factor receptor (EGFR) exon 19 deletion or L858R mutations whose disease had progressed after treatment with osimertinib and platinum chemotherapy.[i] While previously reported results have demonstrated durable responses with RYBREVANT® in combination with lazertini...
Source: Johnson and Johnson - September 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
